Back to discover

Protein / target

Pulmonary surfactant-associated protein D

Encoded bySFTPDP35247Homo sapiensSwiss-Prot
UniProt: P35247Ensembl: ENSG00000133661HGNC: HGNC:10803NCBI Gene: 6441
Small-molecule tractable
Druggability
Structure with Ligand
1
Research papers

Protein at a glance

Biological role

Identical protein binding

Strongest disease association

COVID-19

Via encoding gene SFTPD · Genetic evidence · score 0.76

Research activity

Emerging research

1 papers · latest 2024

Derived from structured UniProt, Open Targets and literature data on this page.

Protein profile

UniProt 2026_02

Canonical identity and biological annotation from UniProt.

Function overview

Contributes to the lung's defense against inhaled microorganisms, organic antigens and toxins.

View complete UniProt function annotation

Contributes to the lung's defense against inhaled microorganisms, organic antigens and toxins. Interacts with compounds such as bacterial lipopolysaccharides, oligosaccharides and fatty acids and modulates leukocyte action in immune response. May participate in the extracellular reorganization or turnover of pulmonary surfactant. Binds strongly maltose residues and to a lesser extent other alpha-glucosyl moieties

Subcellular location

Secreted, extracellular space, extracellular matrixSecreted, extracellular space, surface film
Domains and Gene Ontology detail (23)

Domains & features

Collagen-likeC-type lectin

Gene Ontology

  • Cclathrin-coated endocytic vesicle
  • Cendocytic vesicle
  • Cendoplasmic reticulum membrane
  • Cextracellular region
  • Cextracellular space
  • Clysosome
  • Cmultivesicular body
  • Fcarbohydrate binding
  • Fidentical protein binding
  • Pdefense response to bacterium
  • Pinnate immune response
  • Plung alveolus development

375 aa · 38 kDa

Biological roles

What this protein does, drawn together from its UniProt function, Gene Ontology terms and Reactome pathways.

Cell migrationGOLipid & lipoprotein metabolismUniProtImmune signallingUniProt · GO
View supporting evidence

Cell migration

  • ·macrophage chemotaxis

Lipid & lipoprotein metabolism

  • ·Contributes to the lung's defense against inhaled microorganisms, organic antigens and t…

Immune signalling

  • ·Contributes to the lung's defense against inhaled microorganisms, organic antigens and t…
  • ·innate immune response
  • ·negative regulation of interleukin-2 production
  • ·negative regulation of T cell proliferation

Concepts derived from UniProt GO Reactome — each badge above shows which sources supported that role.

Translational evidence

Open Targets 26

Why this target matters therapeutically, strongest evidence first. Disease associations are gene-level (via the gene that encodes this protein) and open into the full confidence synthesis; the development universe, tractability and safety annotations are target-level, from Open Targets.

Strongest disease associations · via encoding gene SFTPD

Gene-level evidence surfaced through the gene SFTPDthat encodes this protein — not a direct protein–disease relationship. Ranked by Forefront's causal-directness weighting, so genetically- and clinically-evidenced diseases lead over ones that merely share the literature.

COVID-19
0.84Well supported

Genetic evidence dominant · Open Targets 0.56

Liver Diseases
0.51Moderately supported

Genetic evidence dominant · Open Targets 0.31

Severe Acute Respiratory Syndrome
0.44Preliminary

Pathway evidence dominant · Open Targets 0.39 · no direct causal or clinical evidence

Pulmonary Disease, Chronic Obstructive
0.42Limited support

Genetic evidence dominant · Open Targets 0.22

Familial lipoprotein lipase deficiency
0.38Limited support

Genetic evidence dominant · Open Targets 0.23

View evidence synthesis (5)
COVID-19Well supported
0.84
agreement 0.72–0.96
Genetic68%Pathway22%Literature10%

Open Targets aggregate 0.56 · 3 independent evidence families

Liver DiseasesModerately supported
0.51
agreement 0.37–0.65
Genetic99%Literature1%

Open Targets aggregate 0.31 · 2 independent evidence families

Severe Acute Respiratory SyndromePreliminary
0.44
agreement 0.30–0.58
Pathway47%Animal model38%Literature14%

Open Targets aggregate 0.39 · 3 independent evidence families · no direct causal or clinical evidence

Pulmonary Disease, Chronic ObstructiveLimited support
0.42
agreement 0.28–0.56
Genetic69%Literature31%

Open Targets aggregate 0.22 · 2 independent evidence families

Familial lipoprotein lipase deficiencyLimited support
0.38
agreement 0.26–0.50
Genetic100%

Open Targets aggregate 0.23 · 1 independent evidence family

The evidence agreement range shows how closely the independent evidence families agree — it is not a statistical confidence interval, and nothing here is fitted to outcome data. Derived from Open Targets evidence types under Forefront weighting; the per-type scores above show the calculation.

Show all associations
COVID-190.56
Severe Acute Respiratory Syndrome0.39
Liver Diseases0.31
Familial lipoprotein lipase deficiency0.23
Pulmonary Disease, Chronic Obstructive0.22
Idiopathic Pulmonary Fibrosis0.13
Lung Diseases, Interstitial0.13
Respiratory Distress Syndrome0.11
Cystic Fibrosis0.10
Asthma0.10

Tractability

Small molecules — Emerging

Feasibility evidence (structure with ligand and high-quality pocket) — no clinical-stage drug of this modality recorded.

Antibodies — Emerging

Feasibility evidence (go cc high conf and uniprot loc med conf) — no clinical-stage drug of this modality recorded.

View underlying tractability evidence (5)
SM · Structure with LigandSM · High-Quality PocketAB · GO CC high confAB · UniProt loc med confAB · UniProt SigP or TMHMM

Raw Open Targets tractability assessment buckets, by modality.

Research activity

1 papers · to 2024

Papers linked directly to this protein. This is the protein's own literature — descriptor-derived papers are kept separate below.

Most cited

Revisiting surfactant protein D: an immune surveillance molecule bridging innate and adaptive immunity.12 cites

Shamim A · Frontiers in immunology · 2024

Recent

Revisiting surfactant protein D: an immune surveillance molecule bridging innate and adaptive immunity.

Shamim A · Frontiers in immunology · 2024

Europe PMC papers linked directly to this protein.